Cofactor Genomics showcased compelling new validation data for its RNA-based diagnostic platform, OncoPrism®, at the RNA Society’s 30th Annual Meeting. Dr. Kevin Flanagan, the company’s VP of Translational Science, presented a session titled “Bringing Precision Medicine to Cancer Immunotherapy with a Robust RNA Diagnostic Platform.” The presentation revealed how OncoPrism delivers a 300–400% improvement in predicting cancer immunotherapy outcomes compared to existing diagnostic tools.

Leveraging AI and patient tumor RNA expression profiles, OncoPrism significantly enhances clinicians’ ability to identify patients most likely to benefit from immune checkpoint inhibitors. Notably, Cofactor also shared the first validation results of OncoPrism-NSCLC, a version designed for non-small cell lung cancer (NSCLC)—the largest group of patients eligible for immunotherapy. Validated across 12 clinical sites, OncoPrism-NSCLC outperformed the widely used PD-L1 test in both sensitivity and specificity.

Cofactor’s precision medicine approach is already making an impact in the clinic. Both OncoPrism-HNSCC and OncoPrism-NSCLC are available for use through its CAP-accredited, CLIA-certified lab, and OncoPrism-HNSCC has already received Medicare reimbursement approval. The strength of this platform lies in its proprietary Health Expression Models—advanced RNA profiles built using machine learning to capture the immune state of tumor environments with remarkable accuracy.

“OncoPrism is helping close the precision medicine gap,” said Dr. Flanagan. “By harnessing RNA’s depth, we’re equipping doctors with tools that outpace conventional biomarkers in predicting immunotherapy response.”

The company’s presence at the RNA Society’s landmark 30th meeting reflects a major milestone in RNA research. By demonstrating how RNA diagnostics like OncoPrism are guiding real-world treatment decisions and improving outcomes, Cofactor reaffirmed RNA’s pivotal role in the future of personalized cancer care.

Explore More Cutting-Edge Tech Like This – Stay ahead of the game. Visit IT Tech News for more insights on AI, data tech, and innovation shaping our future.

News Source: Businesswire.com